Circle Pharma, a clinical-stage biopharmaceutical company headquartered in San Francisco, raised $90 million in a Series D funding round.
The investment round was led by The Column Group with additional participation from new and existing investors, including Nextech Invest and Euclidean Capital.
According to the official press announcement, Circle Pharma intends to use the fresh funds to accelerate the clinical development of its CID-078, a novel cyclin A/B inhibitor designed to target specific protein interactions that play critical roles in diseases such as cancer.
Additionally, the funding will enable Circle Pharma to advance its portfolio of drug discovery programs powered by its proprietary MXMO™ macrocycle platform. The platform facilitates the design of innovative therapies that address hard-to-treat targets through cell-permeable macrocycles, with the potential for oral delivery.
Led by CEO David Earp, Circle Pharma is focused on tackling challenging medical needs by creating therapies for diseases like cancer using its cutting-edge technology.